Sanofi

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 16:55:00 09/12/2025 GMT			5-day change	1st Jan Change
83.23 ^EUR	-0.44%		-3.88%	-11.21%

12-09	Guggenheim Downgrades Sanofi to Neutral From Buy	MT
12-09	US FDA launches fresh safety scrutiny of approved RSV therapies for infants	RE

Sanofi to Invest EUR300 Million in France to Accelerate AI Strategy

Sebastien Foll

Published on 11/17/2025 at 01:43 pm GMT

- Translated by Marketscreener - See original

Sanofi

-0.44%

Sanofi announced on Monday its plan to dedicate EUR300 million to the development of new equipment focused on artificial intelligence (AI) in France. This sum will be in addition to the EUR700 million in projects already scheduled to modernize its industrial facilities in the country between 2025 and 2026.

The pharmaceutical group specified that these investments will complement the EUR2.5 billion it invests annually in research in France, making it the nation's leading private investor in R&D across all sectors for several years running.

On the occasion of the first 'Choose France' summit dedicated to French businesses, Sanofi reaffirmed France's crucial role in its industrial, scientific, and digital strategies. Nearly 30% of its global workforce dedicated to digital professions is currently based in France.

Since the Covid pandemic, Sanofi estimates it has invested more than EUR3.5 billion in the establishment of strategic platforms for the production of medicines and vaccines. Since 2022, the group has unlocked nearly EUR1 billion to provide France with a comprehensive, end-to-end strategic capacity and value chain for messenger RNA (mRNA).

Latest news about Sanofi

12-09	Guggenheim Downgrades Sanofi to Neutral From Buy	MT
12-09	US FDA launches fresh safety scrutiny of approved RSV therapies for infants	RE
12-09	U.S. FDA officials inform Merck, Sanofi and AstraZeneca RSV antibody therapies would receive fresh safety scrutiny - sources familiar with the situation	RE
12-09	Gan & Lee Pharmaceuticals Gets Clinical Trial Approval For Atopic Dermatitis Drug	MT
12-08	Sanofi warns of Insulin Lispro pen shortage says EMA	RE
12-08	European Equities Traded in the US as ADRs Little Changed in Monday Trading	MT
12-08	SANOFI : JP Morgan is Neutral	ZD
12-05	SANOFI : Buy rating from Bernstein	ZD
12-05	Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns	RE
12-05	European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading	MT
12-06	Kennedy's advisers scrap hepatitis B vaccine guidance for most children in major policy shift	RE
12-04	Sanofi completed the acquisition of Vicebio Limited from Medicxi Ventures (UK) LLP, TCG Crossover Management, LLC, venBio LLC, Goldman Sachs Asset Management International, UniQuest Pty Limited and Avoro Capital Advisors LLC.	CI
12-04	Sanofi Completes Vicebio Acquisition to Add Respiratory Vaccine Candidate	MT
12-04	Sanofi Closes on UK Biotechnology Company Vicebio	MT
12-04	Kennedy advisers delay vote to drop hepatitis B vaccine recommendation, a major policy shift	RE
12-04	Sanofi Completes Acquisition of Vicebio
12-04	Sanofi completes acquisition of Vicebio	RE
12-04	LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-Driven Antibody Optimisation Programs	CI
12-04	Sanofi Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 03:15 PM
12-03	Sanofi Presents at Evercore 8th Annual Healthcare Conference, Dec-02-2025 11:30 AM
12-02	Ovid Therapeutics Inc. Appoints Petra Kaufmann as Chief Medical Officer	CI
12-01	Regeneron Pharmaceuticals, Inc. and Tessera Therapeutics, Inc. to Jointly Develop Tsra-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency	CI
12-01	Tyra Biosciences, Inc. Appoints Heather Faulds as Chief Regulatory Officer, Effective December 8, 2025	CI
11-28	European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Gain 4% for Week	MT
11-26	CG Oncology, Inc. Announces Board and Committee Changes	CI

Chart Sanofi

Duration

Period

SAN: Dynamic Chart

Company Profile

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (79.8%): prescription drugs in the areas of specialty medicine (63.2% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (36.8%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (20.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2024, the group had 52 production sites worldwide. In October 2024, the consumer healthcare products business (Opella) was classified as a discontinued operation. Net sales are distributed geographically as follows: France (4.4%), Europe (17.6%), the United States (48.7%), China (6.5%) and other (22.8%).

Employees

82,878

Sector

Pharmaceuticals

Calendar

01-29 - Q4 2025 Earnings Release

More about the company